Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new pill beat a standard heart drug for a stiff heart condition?

NCT ID NCT07755904

Disease control Sponsor: Braveheart Bio, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This phase 3 trial is testing whether an experimental drug called BHB-1893 works better than the standard beta-blocker metoprolol for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle thickens and blocks blood flow. The study will enroll about 210 adults who are either already being treated for oHCM or have not yet started treatment. Participants will be randomly assigned to receive either BHB-1893 or metoprolol, and the main goal is to see if BHB-1893 improves exercise capacity (measured by peak oxygen uptake) more than metoprolol.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BHB-1893 (an experimental oral drug)
What this could lead to
If BHB-1893 outperforms metoprolol, it could offer a new, more effective treatment option for people with obstructive hypertrophic cardiomyopathy, potentially improving their exercise capacity and quality of life.
What could go wrong
This is a phase 3 trial, but success is not guaranteed. BHB-1893 may not prove superior to metoprolol, and like any drug, it carries risks of side effects. The results will need careful review before any conclusions are drawn.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Diagnosed with oHCM per the protocol specified criteria * NYHA Class II or III at screening visits * KCCQ-CSS that meets the protocol specified criteria at screening visits * Adequate acoustic windows for echocardiography Key Exclusion Criteria: * Medical indication for either β-blocker or calcium-channel blocker therapy, other than oHCM, prohibiting drug discontinuation * History of intolerance or medical contraindication to β-blocker therapy * Resting systolic blood pressure (SBP) of \>160 millimeters of mercury (mmHg) at screening visits * Resting heart rate of \>100 beats per minute (bpm) at screening visits * Significant valvular heart disease, defined as: * Moderate to severe valvular aortic stenosis or fixed subaortic obstruction; * Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator's judgment) Other protocol-defined criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiomyopathy, hypertrophic obstructive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiomyopathy, hypertrophic obstructive

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.